Neumora Therapeutics, Inc. (NMRA)
| Market Cap | 295.95M +142.5% |
| Revenue (ttm) | n/a |
| Net Income | -222.39M |
| EPS | -1.33 |
| Shares Out | 182.69M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 600,977 |
| Open | 1.680 |
| Previous Close | 1.630 |
| Day's Range | 1.605 - 1.710 |
| 52-Week Range | 0.716 - 3.650 |
| Beta | 2.76 |
| Analysts | Buy |
| Price Target | 8.91 (+450.0%) |
| Earnings Date | May 7, 2026 |
About NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for NMRA stock is "Buy." The 12-month stock price target is $8.91, which is an increase of 450.00% from the latest price.
News
Neumora Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum, re-elected Class III directors, ratified Ernst & Young as auditor, and approved executive compensation and annual advisory votes. Final results will be filed with the SEC.
Neumora Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Navacaprant phase III studies were optimized for patient selection and will report data this quarter, with NDA strategy possibly using pooled and safety data. NMRA-511 shows efficacy in Alzheimer's agitation; more studies are planned. NMRA-215 shows semaglutide-like weight loss preclinically, and NMRA-898 advances with strong CNS properties and upcoming data.
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target...
Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)
“We focused on steady execution during the first quarter, highlighted by the full enrollment of the navacaprant KOASTAL-2 and -3 studies with more than 400 patients per study. We look…
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer's disease agitation and ...
Neumora Therapeutics Earnings release: Q1 2026
Neumora Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Neumora Therapeutics Slides: Q1 2026
Neumora Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Neumora Therapeutics Quarterly report: Q1 2026
Neumora Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Neumora Therapeutics Proxy statement: Proxy filing
Neumora Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Neumora Therapeutics Proxy statement: Proxy filing
Neumora Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Neumora Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Four clinical programs are advancing, with major data readouts for navacaprant in MDD expected in Q2 and promising progress in Alzheimer's agitation, obesity, and muscarinic schizophrenia assets. Regulatory flexibility and robust financials support multiple upcoming catalysts.
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that targ...
Neumora Therapeutics management to meet with Piper Sandler
Meeting to be held on April 6 hosted by Piper Sandler.
Neumora Therapeutics Earnings Call Transcript: Q4 2025
Significant clinical progress in 2025 included positive NMRA-511 and NMRA-215 data, full enrollment of Navacaprant phase III studies, and advancement of NMRA-898 for schizophrenia. Cash runway extends into Q3 2027, with multiple clinical milestones expected in 2026.
Neumora Therapeutics Annual report: Q4 2025
Neumora Therapeutics has published its Q4 2025 annual report on March 30, 2026.
Neumora Therapeutics Earnings release: Q4 2025
Neumora Therapeutics released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)
“We saw significant progress in 2025, laying the foundation for a catalyst-rich year ahead as we advance our pipeline of next-generation therapies for people living with brain diseases,” said Paul…
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies
Neumora Therapeutics Slides: Corporate presentation
Neumora Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 30, 2026.
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that targ...
Neumora Therapeutics management to meet virtually with Needham
Virtual Meeting to be held on March 3 hosted by Needham.
Neumora upgraded to Outperform from Market Perform at William Blair
William Blair analyst Myles Minter upgraded Neumora Therapeutics (NMRA) to Outperform from Market Perform with a net present value estimate of $7.62 per share. The firm increased its probability of…
Neumora Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
New phase I-B data for NMRA-511 in Alzheimer's agitation show strong efficacy and safety, with plans for higher dosing and pivotal studies. NMRA-215 is advancing for obesity with a focus on CNS penetration, and key pipeline updates are expected mid-year. Operations are funded into Q3 2027.
Neumora Therapeutics Slides: Corporate presentation
Neumora Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on February 10, 2026.
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that targe...